Faculty profile

Marc-André Langlois

Back to faculty

Associate ProfessorBiochemistry, Microbiology and ImmunologyUniversity of Ottawa

Marc-André Langlois

Associate Professor

Biochemistry, Microbiology and Immunology

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
7 publications in the last five years, latest in 2026.
Principal investigator on 20 research grants (17 CIHR, 2 NSERC, 1 SSHRC), most recently in 2025.
Supervisor on 1 trainee award (1 CIHR), most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Personal Website Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Covid-19 Sars-Cov-2 Antibodies Molecular Virology Cellular Immunity Serology Viral Load Testing Virus Neutralization

Latest papers

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.
Journal of clinical immunology · 2026
Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies
British Journal of Haematology · 2025
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies
Vaccine · 2024

All 7 publications

Latest funding

Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada
CIHR · 2025 · Nominated PI
$2,999,998
Molecular and Antibody Surveillance of H5N1 in Animals and Humans using a High Throughput Diagnostic Platform
CIHR · 2024 · Nominated PI
$150,000
Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).
CIHR · 2023 · Co-investigator
$5,222,039

All 28 grants and awards

7 publications.

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.

Porto LLTN, Yazji D, Unninayar D, Decaluwe H, Derfalvi B, Palma A, Issekutz T, Kalashnikova T, Murguía-Favela L, Pham-Huy A, Rubin T, Suresh S, Upton J, Wright NAM, Chapdelaine H, Falcone EL, Top KA, Sadarangani M, Vinh DC, Barrett L, Oldford S, Langlois MA, Arnold C, Zhang T, Ramsay T, Cowan J, VISID study investigators

Journal of clinical immunology2026

DOI: 10.1007/s10875-026-02021-1 PMID: 42034835

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

Vijenthira A, Bhella S, Hueniken K, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Balitsky A

British Journal of Haematology2025

DOI: 10.1111/bjh.70054

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G

Vaccine20247 citations

DOI: 10.1016/j.vaccine.2024.06.041

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Unninayar D, Falcone EL, Chapdelaine H, Vinh DC, Top KA, Derfalvi B, Issekutz TB, Decaluwe H, Pham-Huy A, Upton J, Betschel SD, Rubin T, Suresh S, Wright NAM, Murguía-Favela L, Kalashnikova T, Barrett L, Oldford S, Langlois MA, Arnold C, Sadarangani M, Zhang T, Ramsay T, Yazji D, Cowan J

Frontiers in immunology2024

DOI: 10.3389/fimmu.2024.1501908 PMID: 39906736

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5.

Sakr E, Almeida ND, Langlois MA, Dasgupta K, Mazer BD

The Journal of allergy and clinical immunology2024

DOI: 10.1016/j.jaci.2023.11.912 PMID: 38159096

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.

Almeida ND, Schiller I, Ke D, Sakr E, Plesa M, Vanamala S, Moneger AL, Bazan M, Lucchesi C, Wozniak N, Fritz JH, Piccirillo CA, Pelchat M, Arnold C, Galipeau Y, McCluskie PS, Langlois MA, Dasgupta K, Mazer BD

Frontiers in immunology2024

DOI: 10.3389/fimmu.2024.1330549 PMID: 38433831

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.

Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, Saginur R, Booth R, Little J, McGuinty M, Buchan CA, Crawley A, Langlois MA, Cooper C

BMJ open2023

DOI: 10.1136/bmjopen-2023-077714 PMID: 37907304

Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada

Nominated PICIHR2025Operating Grant: Pandemic Research Platforms Interim Funding - General

Principal investigators: Langlois, Marc-Andre

Keywords: Antibodies; Clinical Trials For Vaccines; Elisa; Emerging Infectious Diseases; High Throughput Automation; Knowledge Mobilization; Molecular Diagnostics; Pandemic Preparedness; Qpcr; Sero-Surveillance (Population-Level)

$2,999,998

Molecular and Antibody Surveillance of H5N1 in Animals and Humans using a High Throughput Diagnostic Platform

Nominated PICIHR2024Catalyst Grant: Avian Influenza OneHealth Research

Principal investigators: Langlois, Marc-Andre

Keywords: H5n1; High Throughput Automation; Highly Pathogenic Avian Influenza (Hpai); Molecular Detection (Pcr, Qpcr); One Health; Serosurveillance And Antibody Testing; Surrogate Viral Neutralizing Assay; Surveillance Study

$150,000

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$5,222,039

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$1,305,510

COVID-19 seroepidemiology in children Using Retrieved POPCORN site Leftover Samples (CURNLS)

Co-investigatorCIHR2022Operating Grant: POPCORN Supplement

Principal investigators: Quach-Thanh, Caroline; Galanis, Eleni; Strang, Robert A; Basta, Nicole; Bhatt, Maala; Buchanan, Francine; Constantin, Evelyn; Côté, Sylvana; Drouin, Olivier; Dugas, Marc-André; Fontela, Patricia S; Foo, Cheryl P; Foster, Jennifer; Freedman, Stephen B; Gagneur, Arnaud A; Gantt, Soren M; Gill, Peter J; Kakkar, Fatima; Kellner, James D; Klassen, Terry P; Lacaze-Masmonteil, Thierry; Lalgudi Ganesan, Saptharishi; Li, Patricia T; Mahant, Sanjay; Mater, Ahmed; Muttalib, Fiona; Papenburg, Jesse; Sadarangani, Manish; Sehgal, Anupam V; 't Jong, Geert W; Wahi, Gita; Wright, Bruce

Keywords: Covid 19

The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations

Co-investigatorCIHR2021Op. Gr.: Addr. Wider Impacts of COVID-Imp. on social/econ/pop iss/pbl outcomes

Principal investigators: Liu, Peter P

Keywords: Covid-19; Health Outcomes; Hospitalization; Mortality; Racial Disparities; Social Impacts; Underrepresented Populations; Visible Minorities

$498,210

Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Study

Principal investigatorCIHR2021Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Vaccines

Principal investigators: El-Chaar, Darine; Langlois, Marc-Andre; McGuinty, Michaeline

Keywords: Breastfeeding; Covid-19 Vaccines; Immunogenicity; Infant Outcomes; Maternal Newborn Health; Pregnancy

$500,000

Vaccine effectiveness against SARS-CoV-2 variants of concern in long-term care populations: a multi-province study

Principal investigatorCIHR2021Operating Grant: Emerging COVID-19 Research Gaps and Priorities - Variants

Principal investigators: Hsu, Amy T; Langlois, Marc-Andre; McGrail, Kimberlyn M; Strumpf, Erin C; Wilson, Kumanan

Keywords: Covid-19; Immunology; Long-Term Care; Vaccine Effectiveness; Variants Of Concern

Coronavirus Variants Rapid Response Network: CoVaRR-Net

Nominated PICIHR2021Operating Grant: CIHR Network for Emerging COVID-19 Variants Research

Principal investigators: Langlois, Marc-Andre; Brouwers, Melissa C; Flamand, Louis; Gingras, Anne-Claude; Gommerman, Jennifer L; Muhajarine, Nazeem; Ragoussis, Ioannis; Shapiro, Jesse

Keywords: Covarr-Net; Covid-19; Rapid-Response; Sars-Cov-2; Variants Of Concern

$9,000,000

Role of antibodies in platelet response to SARS-CoV-2 and its variants

Co-investigatorCIHR2021Op Grant: Emerging COVID-19 Research Gaps & Priorities - Post COVID-19 condition

Principal investigators: Boilard, Eric

Keywords: Antibodies; Inflammation; Platelets; Sars-Cov-2; Thrombosis; Variants

$261,700

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Covid-19 Dear Professor Langlois, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 26, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Marc-André Langlois

Research

Latest papers

Latest funding

Three Doses and Six Months Later: Real-World SARS-CoV-2 Specific Humoral and Cell-Mediated Immunity in Children With Inborn Errors of Immunity.

Incremental immunogenicity of multiple doses of SARS‐CoV‐2 vaccination in patients with haematological malignancies

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5.

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study.

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination.

Empowering Large-Scale Infectious Disease Research and Mobilizing Knowledge: The Serology and Diagnostics High-Throughput Platform as Critical Research Infrastructure for Pandemic Preparedness, Surveillance, and Response in Canada

Molecular and Antibody Surveillance of H5N1 in Animals and Humans using a High Throughput Diagnostic Platform

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

COVID-19 seroepidemiology in children Using Retrieved POPCORN site Leftover Samples (CURNLS)

The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations

Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Study

Vaccine effectiveness against SARS-CoV-2 variants of concern in long-term care populations: a multi-province study

Coronavirus Variants Rapid Response Network: CoVaRR-Net

Role of antibodies in platelet response to SARS-CoV-2 and its variants

Frequent collaborators

Curtis Cooper

Juthaporn Cowan

Manish Sadarangani

Beata Derfalvi

Kaberi Dasgupta

Amaris Karin Balitsky

Michael Sebag

Martin Pelchat

Michaeline McGuinty

Julian Little

Ronald Booth

Raphael Saginur

Angela Crawley

Thomas Issekutz